DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Direct therapeutic targeting of dystrophin deficiency is critical, however, hindered by the large size of the dystrophin cDNA and/or stochastic, often extensive genetic changes in DMD gene.